Active Stocks
Wed Jun 19 2024 15:54:35
  1. HDFC Bank share price
  2. 1,658.00 3.06%
  1. Tata Steel share price
  2. 180.05 -0.61%
  1. State Bank Of India share price
  2. 852.60 0.95%
  1. ITC share price
  2. 423.70 -1.19%
  1. ICICI Bank share price
  2. 1,144.75 1.93%
Business News/ Markets / Stock Markets/  Diwali Muhurat Trading 2023: Glenmark Pharma share price opens almost 10% lower after Q2 result
BackBack

Diwali Muhurat Trading 2023: Glenmark Pharma share price opens almost 10% lower after Q2 result

Glenmark Pharma reported a 6.3% YoY increase in consolidated revenue and an 8.3% YoY increase in adjusted EBITDA for Q2 FY24.

Glenmark Pharma share price opened almost 10 per cent lower on the occasion of Diwali Muhurat Trading 2023 on Friday. (Pixabay)Premium
Glenmark Pharma share price opened almost 10 per cent lower on the occasion of Diwali Muhurat Trading 2023 on Friday. (Pixabay)

Glenmark Pharma share price opened almost 10 per cent lower on the occasion of Diwali Muhurat Trading 2023 on Friday, November 12. The stock opened at 702.05 against the previous close of 777.60. However, it pared losses sharply and traded 1.04 per cent lower at 769.55 around 6:20 pm on BSE.

The pharma company on November 10 reported a consolidated revenue growth of 6.3 per cent and adjusted EBITDA growth of 8.3 per cent year-on-year (YoY) for Q2 FY24.

"For the second quarter of FY24, Glenmark’s consolidated revenue was at 3,587.9 crore as against 3,375.2 crore recording an increase of 6.3 per cent YoY. Adjusted EBITDA was at 673.2 crore in the quarter ended Sept 30, 2023, as against 621.6 crore in the previous corresponding quarter, registering an increase of 8.3 per cent YoY, and margins of 18.8 per cent," Glenmark Pharma said in its exchange filing.

Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd. Said, “We maintained a strong growth momentum during the quarter that was led by Europe and the RoW markets. We continue to take strides and move up the value chain with the in‐licensing of Winlevi for Europe and South Africa."

"The recently announced proposed divestment of 75 per cent stake in Glenmark Life Sciences is another step in this direction. Our first global brand, Ryaltris, has demonstrated robust growth across the 29 markets in which it is already present. Our partner in China successfully completed the Phase 3 clinical trial on Ryaltris; with the product meeting the primary endpoint. We are expecting to launch it in newer markets over the course of the year."

The company's sales from the formulation business in India in Q2FY24 was at 1,121.7 crore, up 2.8 per cent YoY. Its North America segment registered revenue from the sales of finished dosage formulations of 739.2 crore, recording a decline of 1.9 per cent YoY. Revenue from Asia, MEA, LATAM and RCIS Region (RoW) grew 19 per cent YoY while Glenmark Europe’s operations revenue grew 58.4 per cent YoY, according to the company's exchange filing.

Read all market-related news here

Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decisions.

3.6 Crore Indians visited in a single day choosing us as India's undisputed platform for General Election Results. Explore the latest updates here!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 12 Nov 2023, 06:43 PM IST
Next Story footLogo
Recommended For You
GENIE RECOMMENDS

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started